Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma

Liver International

Volumn 35, Issue 6, 2015, Pages 1715-1721

  Kolligs, Frank T ^a   Bilbao, Jose I ^b   Jakobs, Tobias ^c   Iñarrairaegui, Mercedes ^a   Nagel, Jutta M ^a   Rodriguez, Macarena ^d   Haug, Alexander ^a   D'Avola, Delia ^d   op den Winkel, Mark ^a   Martinez Cuesta, Antonio ^e   Trumm, Christoph ^a   Benito, Alberto ^d   Tatsch, Klaus ^f   Zech, Christoph J ^g   Hoffmann, Ralf Thorsten ^h   Sangro, Bruno ^d  

^a UNIVERSITY OF MUNICH   (Germany)

^b Recinto de Complejo Hospitalario de Navarra   (Spain)

^c KRANKENHAUS BARMHERZIGE BRÜDER   (Germany)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

^e Universidad Pública de Navarra   (Spain)

^f Municipal Hospital of Karlsruhe Inc   (Germany)

^g UNIVERSITY OF BASEL   (Switzerland)

^h UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Chemoembolization; Intermediate stage HCC; Radioembolization; Yttrium 90

Indexed keywords

ALBUMIN; BILIRUBIN; EPIRUBICIN; IODINATED POPPYSEED OIL; MICROSPHERE; YTTRIUM 90; YTTRIUM;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; ASCITES; BILIRUBIN BLOOD LEVEL; CANCER GROWTH; CANCER RADIOTHERAPY; CHEMOEMBOLIZATION; CHILD PUGH SCORE; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; ELECTROCORTICOGRAPHY; EVALUATION STUDY; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERBILIRUBINEMIA; INFECTION; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MALE; MULTICENTER STUDY; OPEN STUDY; PILOT STUDY; PNEUMONIA; PROSPECTIVE STUDY; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS; SELECTIVE INTERNAL RADIATION THERAPY; SIDE EFFECT; TRANSARTERIAL CHEMOEMBOLIZATION; TREATMENT RESPONSE; TUMOR VOLUME; ADVERSE EFFECTS; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; COMPARATIVE STUDY; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

AGED; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED; NEOPLASM STAGING; PILOT PROJECTS; PROSPECTIVE STUDIES; QUALITY OF LIFE; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 84929128355     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12750     Document Type: Article

References (28)

1. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-9.
2. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-71.
3. Sangro B, Carpanese L, Cianni R, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 2011; 54: 868-78.
4. Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011; 140: e492.
5. Hilgard P, Hamami M, Fouly AE, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 2010; 52: 1741-9.
6. Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009; 9: 1920-8.
7. Inarrairaegui M, Pardo F, Bilbao JI, et al. Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma. Eur J Surg Oncol 2012; 38: 594-601.
8. Riaz A, Kulik L, Lewandowski RJ, et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 2009; 49: 1185-93.
9. Loewe C, Cejna M, Schoder M, et al. Arterial embolization of unresectable hepatocellular carcinoma with use of cyanoacrylate and lipiodol. J Vasc Interv Radiol 2002; 13: 61-9.
10. Steel J, Baum A, Carr B. Quality of life in patients diagnosed with primary hepatocellular carcinoma: hepatic arterial infusion of Cisplatin versus 90-Yttrium microspheres (Therasphere). Psychooncology 2004; 13: 73-9.
11. Signorini DF, Leung O, Simes RJ, et al. Dynamic balanced randomization for clinical trials. Stat Med 1993; 12: 2343-50.
12. Meza-Junco J, Montano-Loza AJ, Liu DM, et al. Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how? Cancer Treat Rev 2012; 38: 54-62.
13. Raoul JL, Sangro B, Forner A, et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011; 37: 212-20.
14. Sangro B, Bilbao JI, Boan J, et al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2006; 66: 792-800.
15. Heffernan N, Cella D, Webster K, et al. Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy-hepatobiliary questionnaire. J Clin Oncol 2002; 20: 2229-39.
16. Steel JL, Eton DT, Cella D, Olek MC, Carr BI. Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinoma. Ann Oncol 2006; 17: 304-12.
17. Memon K, Kulik L, Lewandowski RJ, et al. Prospective evaluation of patients with early-/intermediate-stage hepatocellular carcinoma with disease progression following arterial locoregional therapy: candidacy for systemic treatment or clinical trials. J Vasc Interv Radiol 2013; 24: e1182.
18. Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138: 52-64.
19. Shun SC, Chen CH, Sheu JC, et al. Quality of life and its associated factors in patients with hepatocellular carcinoma receiving one course of transarterial chemoembolization treatment: a longitudinal study. Oncologist 2012; 17: 732-9.
20. Eltawil KM, Berry R, Abdolell M, Molinari M. Quality of life and survival analysis of patients undergoing transarterial chemoembolization for primary hepatic malignancies: a prospective cohort study. HPB 2012; 14: 341-50.
21. Salem R, Gilbertsen M, Butt Z, et al. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol 2013; 11: e1351.
22. Wible BC, Rilling WS, Drescher P, et al. Longitudinal quality of life assessment of patients with hepatocellular carcinoma after primary transarterial chemoembolization. J Vasc Interv Radiol 2010; 21: 1024-30.
23. Salem R, Miller FH, Yaghmai V, Lewandowski RJ. Response assessment methodologies in hepatocellular carcinoma: complexities in the era of local and systemic treatments. J Hepatol 2013; 58: 1260-2.
24. Dufour JF, Bargellini I, De Maria N, et al. Intermediate hepatocellular carcinoma: current treatments and future perspectives. Ann Oncol 2013; 24(Suppl. 2): ii24-9.
25. Pietrosi G, Miraglia R, Luca A, et al. Arterial chemoembolization/embolization and early complications after hepatocellular carcinoma treatment: a safe standardized protocol in selected patients with Child class A and B cirrhosis. J Vasc Interv Radiol 2009; 20: 896-902.
26. Gil-Alzugaray B, Chopitea A, Inarrairaegui M, et al. Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology 2013; 57: 1078-87.
27. Kooby DA, Egnatashvili V, Srinivasan S, et al. Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2010; 21: 224-30.
28. Bolondi L, Burroughs A, Dufour JF, et al. Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis 2012; 32: 348-59.